News

Boehringer Ingelheim Has Given NIPER Hajipur Access to Its Global Open Science Platform — 150+ Molecules, Free of Charge, to Researchers in Eastern India

"NIPERs have been identified by the government as centres of excellence for Biopharma SHAKTI. Our view is simple: the greater the number of talented Indian researchers engaged in this mission, the stronger the outcomes for the country."

By Mustafa Shariff, Editor in Chief · April 28, 2026 · 5 min read

Summary

• Boehringer Ingelheim + NIPER Hajipur: What the Open Science Partnership Means for India's Biopharma SHAKTI Mission
• Boehringer Ingelheim India and NIPER Hajipur have signed a 5-year MOU giving Bihar researchers access to the opnMe open science platform. Here is the full story and its significance for India's pharma innovation ecosystem.

Boehringer Ingelheim India and the National Institute of Pharmaceutical Education and Research Hajipur have signed a five-year Memorandum of Understanding to advance pharmaceutical research, education, and innovation — the latest in a series of targeted partnerships that are building India's distributed pharmaceutical research capability from the ground up. The MOU was signed at Kartavya Bhawan in New Delhi in the presence of Manoj Joshi, Secretary of the Department of Pharmaceuticals, Ministry of Chemicals and Fertilisers — signalling the strategic importance the Department attaches to this specific type of industry-academia collaboration.

The centrepiece of the partnership is access to Boehringer Ingelheim's opnMe® platform — a global open science initiative through which the company provides well-characterised, pre-clinical tool compounds to researchers worldwide, free of charge, for use in their scientific studies. The opnMe library currently includes 150+ molecules that Boehringer Ingelheim has shared with Indian institutions, covering a range of molecular targets relevant to inflammation, oncology, cardiovascular disease, and metabolic disorders. Through this MOU, NIPER Hajipur researchers and students gain direct access to these globally validated compounds — the same molecules that scientists at world-class research institutions in the US, UK, and Germany use in their discovery work.

Why This Partnership Is Specifically Designed for Eastern India

Meenal Gauri, Managing Director of Boehringer Ingelheim India, was direct about the geographic rationale: after Boehringer's earlier partnership with NIPER Raebareli in Uttar Pradesh, extending opnMe access to NIPER Hajipur in Bihar brings globally validated research tools to eastern India at this scale for the first time. The deliberate expansion eastward reflects an important policy insight: India's pharmaceutical research capability has historically been concentrated in western and southern India — Maharashtra, Gujarat, Karnataka, Andhra Pradesh, Tamil Nadu. Bihar and the eastern states represent a significant underutilisation of research talent relative to their population and educational base.

Prof. K. Ruckmani, Director of NIPER Hajipur, articulated the institutional mandate: NIPER Hajipur sits at the heart of one of India's most populous regions, and its mandate is to build pharmaceutical research and talent capability that serves Bihar, eastern India, and the country at large. The Boehringer partnership — and specifically the opnMe platform access — gives NIPER Hajipur's researchers and students direct exposure to globally validated pre-clinical tools and world-class R&D collaboration.

What opnMe Enables — The Science Behind the Partnership

The opnMe platform is not a gesture of philanthropy — it is a scientifically substantive resource. Pre-clinical tool compounds are molecules that have been extensively characterised for their biological activity, selectivity, and pharmacological properties at specific molecular targets. Researchers using opnMe compounds can conduct target validation studies — testing whether inhibiting or activating a specific biological target produces the therapeutic effect they predict — with molecules that have already been validated in rigorous pharmacological studies by one of the world's largest pharmaceutical research organisations.

This matters for NIPER Hajipur's researchers because it eliminates one of the most resource-intensive and time-consuming steps in early drug discovery: synthesising and characterising tool compounds from scratch. With opnMe, NIPER scientists can begin studying biological mechanisms immediately using compounds of known quality, generating early-stage proof-of-concept data that can be scaled into preclinical development and potentially licensed or commercialised through the kind of startup and technology transfer mechanisms that Biopharma SHAKTI is designing.

NIPER Hajipur has also separately signed an MOU with the Indian Pharmacopoeia Commission — the national body that sets quality standards for drugs — to advance pharmacopeial standards, impurity profiling, and analytical method validation. Together, these two partnerships give NIPER Hajipur access to both upstream (discovery tool compounds) and downstream (quality standards) capabilities that position it as a more complete pharmaceutical research institution.

The Biopharma SHAKTI Connection

Both Boehringer Ingelheim and the Department of Pharmaceuticals have explicitly framed this partnership in the context of Biopharma SHAKTI — the ₹10,000 crore national mission announced in Budget 2026-27 to build India's biopharmaceutical innovation ecosystem. Biopharma SHAKTI specifically envisions NIPERs as centres of excellence for translational research and pharmaceutical talent development — the institutions through which India builds the next generation of drug discovery scientists who will drive the country's transition from generic manufacturing to innovative drug development.

BHC Perspective

At Bengaluru Health Community, the Boehringer-NIPER Hajipur partnership represents one of the clearest operational examples of how Biopharma SHAKTI is being implemented at the institutional level. Global pharma companies bringing their open science platforms to Indian NIPERs — distributing globally validated research tools that were previously accessible only at well-resourced western institutions — is the talent and capability development mechanism that India needs if it is to build a genuine drug discovery ecosystem rather than simply expanding its manufacturing base.

Frequently Asked Questions

Q: What did Boehringer Ingelheim and NIPER Hajipur sign?
A: A 5-year MOU giving NIPER Hajipur researchers free access to Boehringer Ingelheim's opnMe open science platform — 150+ globally validated pre-clinical tool compounds — for pharmaceutical research and talent development in Bihar and eastern India.

Q: What is the opnMe platform?
A: Boehringer Ingelheim's global open science initiative providing well-characterised pre-clinical tool compounds free of charge to researchers worldwide. Over 150 molecules have been shared with Indian institutions. Access enables researchers to conduct target validation studies without synthesising compounds from scratch.

Q: How does this connect to Biopharma SHAKTI?
A: Biopharma SHAKTI designates NIPERs as centres of excellence for translational research. Industry-academia MoUs like Boehringer-NIPER Hajipur build the discovery capability and talent pipeline that will drive India's transition from generic manufacturing to innovation-led biopharmaceutical development.